RNS Number : 1667X
Alizyme PLC
20 June 2008
For Immediate Release 20 June 2008
Alizyme plc
ALIZYME TO PRESENT AT THE 2008 PIPER JAFFRAY EUROPE CONFERENCE
Cambridge UK, 20 June 2008: Alizyme plc (LSE: AZM) announces that Tim McCarthy, Chief
Executive Officer, will be presenting at the 2008
Piper Jaffray Europe Conference on Tuesday, June 24, 2008 at 3.00pm (BST).
This presentation will be available via live webcast on the Company's website at
www.alizyme.com. A replay of the webcast will also be
available after the conference.
For the live webcast, please ensure that you are logged on approximately10 minutes before
the start of the presentation at 2.50pm
(BST).
For further information, please contact:
ALIZYME plc Tel No: + 44 (0) 1223 896000
Tim McCarthy, Chief Executive Officer
David Campbell, Finance Director
BUCHANAN COMMUNICATIONS Tel No: + 44 (0) 20 7466 5000
Lisa Baderoon
Rebecca Skye Dietrich
Further information on Alizyme can be found on the Company's website: www.alizyme.com
EDITOR'S NOTES
Alizyme is a speciality biopharmaceutical development company, based in Cambridge, UK,
targeting the treatment and management of
gastrointestinal disorders, obesity and diabetes. It has a portfolio of products which
include: cetilistat (prepared for commencement of
Phase III development for the treatment of obesity and diabetes), COLAL-PRED® (in Phase III
development in Europe for the treatment of acute
ulcerative colitis) and ATL-104 (successfully completed a Phase IIa trial for the treatment of
mucositis).
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKGGZVNGLGRZG
|